Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLS5132 + platinum + bevacizumab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
QLS5132 + platinum + bevacizumab is an investigational combination therapy regimen being developed by Qilu Pharmaceutical for the treatment of advanced solid tumors, including gastric, non-small cell lung, endometrial, and ovarian cancers. The regimen consists of QLS5132, an antibody-drug conjugate (ADC) targeting Claudin-6 (CLDN6), combined with platinum-based chemotherapy and bevacizumab, an anti-angiogenic monoclonal antibody. QLS5132 utilizes a humanized anti-CLDN6 IgG1 antibody conjugated to a proprietary topoisomerase-1 inhibitor payload (QLS6916) via a hydrophilic cleavable linker. The combination is designed to provide synergistic anti-tumor activity by combining the targeted cytotoxicity of the ADC, the DNA-crosslinking effects of platinum agents, and the inhibition of vascular endothelial growth factor (VEGF) by bevacizumab to disrupt tumor blood supply.
- Other names
- QLS5132 combination therapyQLS-5132 combination therapyQLS 5132 combination therapy
02
Targets
Beyond the preview
Go deeper on QLS5132 + platinum + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLS5132 + platinum + bevacizumab.